{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:14:06Z","timestamp":1785240846102,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP21K08304"],"award-info":[{"award-number":["JP21K08304"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP24K11477"],"award-info":[{"award-number":["JP24K11477"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16H06279"],"award-info":[{"award-number":["JP16H06279"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020377","name":"Maruho Takagi Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020377","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006567","name":"Suhara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006567","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10147-025-02755-9","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T02:16:36Z","timestamp":1744078596000},"page":"856-866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Genomic profiling and personalized treatment strategies for skin malignancies: findings from the center for cancer genomics and advanced therapeutics database"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3662-0095","authenticated-orcid":false,"given":"Tokimasa","family":"Hida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"2755_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00291","author":"H Ebi","year":"2019","unstructured":"Ebi H, Bando H (2019) Precision oncology and the universal health coverage system in Japan. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.19.00291","journal-title":"JCO Precis Oncol"},{"key":"2755_CR2","unstructured":"Elder D, Barnhill R, Bastian B. Melanocytic tumor classification and the pathway concept of melanoma pathogenesis. In: Elder D, Massi D, Scolyer R, Willemze R (eds). WHO Classification of Skin Tumors, Vol. 11, 4th edn. Lyon, France: IARC, 2018; 66\u201371."},{"key":"2755_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward NK, Wilmott JS, Waddell N et al (2017) Whole-genome landscapes of major melanoma subtypes. Nature 545:175\u2013180. https:\/\/doi.org\/10.1038\/nature22071","journal-title":"Nature"},{"key":"2755_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2022.08.030","volume":"176","author":"Y Nakamura","year":"2022","unstructured":"Nakamura Y, Namikawa K, Kiniwa Y et al (2022) Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: a retrospective, multicenter study of 254 Japanese patients. Eur J Cancer 176:78\u201387. https:\/\/doi.org\/10.1016\/j.ejca.2022.08.030","journal-title":"Eur J Cancer"},{"key":"2755_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100325","volume":"6","author":"Y Nakamura","year":"2021","unstructured":"Nakamura Y, Namikawa K, Yoshikawa S et al (2021) Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study). ESMO Open 6:100325. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100325","journal-title":"ESMO Open"},{"key":"2755_CR6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/bjd.21241","volume":"187","author":"X Bai","year":"2022","unstructured":"Bai X, Shoushtari AN, Betof Warner A et al (2022) Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study. Br J Dermatol 187:401\u2013410. https:\/\/doi.org\/10.1111\/bjd.21241","journal-title":"Br J Dermatol"},{"key":"2755_CR7","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1007\/s10147-024-02615-y","volume":"29","author":"T Hida","year":"2024","unstructured":"Hida T, Kato J, Idogawa M et al (2024) Genomic landscape of cutaneous, acral, mucosal, and uveal melanoma in Japan: analysis of clinical comprehensive genomic profiling data. Int J Clin Oncol 29:1984\u20131998. https:\/\/doi.org\/10.1007\/s10147-024-02615-y","journal-title":"Int J Clin Oncol"},{"key":"2755_CR8","doi-asserted-by":"publisher","first-page":"5259","DOI":"10.1038\/s41467-020-18988-3","volume":"11","author":"F Newell","year":"2020","unstructured":"Newell F, Wilmott JS, Johansson PA et al (2020) Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. Nat Commun 11:5259. https:\/\/doi.org\/10.1038\/s41467-020-18988-3","journal-title":"Nat Commun"},{"key":"2755_CR9","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell F, Kong Y, Wilmott JS et al (2019) Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat Commun 10:3163. https:\/\/doi.org\/10.1038\/s41467-019-11107-x","journal-title":"Nat Commun"},{"key":"2755_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70360","volume":"13","author":"T Hida","year":"2024","unstructured":"Hida T, Idogawa M, Kato J et al (2024) Genetic characteristics of cutaneous, acral, and mucosal melanoma in Japan. Cancer Med 13:e70360. https:\/\/doi.org\/10.1002\/cam4.70360","journal-title":"Cancer Med"},{"key":"2755_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/pcmr.12865","volume":"33","author":"Z Zou","year":"2020","unstructured":"Zou Z, Ou Q, Ren Y et al (2020) Distinct genomic traits of acral and mucosal melanomas revealed by targeted mutational profiling. Pigment Cell Melanoma Res 33:601\u2013611. https:\/\/doi.org\/10.1111\/pcmr.12865","journal-title":"Pigment Cell Melanoma Res"},{"key":"2755_CR12","doi-asserted-by":"publisher","first-page":"9559","DOI":"10.1038\/s41598-022-13391-y","volume":"12","author":"F Huang","year":"2022","unstructured":"Huang F, Li J, Wen X et al (2022) Next-generation sequencing in advanced Chinese melanoma reveals therapeutic targets and prognostic biomarkers for immunotherapy. Sci Rep 12:9559. https:\/\/doi.org\/10.1038\/s41598-022-13391-y","journal-title":"Sci Rep"},{"key":"2755_CR13","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"The Cancer Genome Atlas Network","year":"2015","unstructured":"The Cancer Genome Atlas Network (2015) Genomic classification of cutaneous melanoma. Cell 161:1681\u20131696. https:\/\/doi.org\/10.1016\/j.cell.2015.05.044","journal-title":"Cell"},{"key":"2755_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jdermsci.2015.07.012","volume":"80","author":"K Sakaizawa","year":"2015","unstructured":"Sakaizawa K, Ashida A, Uchiyama A et al (2015) Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients. J Dermatol Sci 80:33\u201337. https:\/\/doi.org\/10.1016\/j.jdermsci.2015.07.012","journal-title":"J Dermatol Sci"},{"key":"2755_CR15","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41467-022-28566-4","volume":"13","author":"F Farshidfar","year":"2022","unstructured":"Farshidfar F, Rhrissorrakrai K, Levovitz C et al (2022) Integrative molecular and clinical profiling of acral melanoma links focal amplification of 22q11.21 to metastasis. Nat Commun 13:898. https:\/\/doi.org\/10.1038\/s41467-022-28566-4","journal-title":"Nat Commun"},{"key":"2755_CR16","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/jnci\/djz005","volume":"111","author":"I Yeh","year":"2019","unstructured":"Yeh I, Jorgenson E, Shen L et al (2019) Targeted genomic profiling of acral melanoma. J Natl Cancer Inst 111:1068\u20131077. https:\/\/doi.org\/10.1093\/jnci\/djz005","journal-title":"J Natl Cancer Inst"},{"key":"2755_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.jid.2017.11.017","volume":"138","author":"KR Moon","year":"2018","unstructured":"Moon KR, Choi YD, Kim JM et al (2018) Genetic alterations in primary acral melanoma and acral melanocytic nevus in Korea: Common mutated genes show distinct cytomorphological features. J Invest Dermatol 138:933\u2013945. https:\/\/doi.org\/10.1016\/j.jid.2017.11.017","journal-title":"J Invest Dermatol"},{"key":"2755_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jdermsci.2023.03.008","volume":"110","author":"T Inozume","year":"2023","unstructured":"Inozume T, Namikawa K, Kato H et al (2023) Analyzing the relationship between the efficacy of first-line immune checkpoint inhibitors and cumulative sun damage in Japanese patients with advanced BRAF wild-type nonacral cutaneous melanoma: A retrospective real-world, multicenter study. J Dermatol Sci 110:19\u201326. https:\/\/doi.org\/10.1016\/j.jdermsci.2023.03.008","journal-title":"J Dermatol Sci"},{"key":"2755_CR19","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/1346-8138.16669","volume":"50","author":"A Takahashi","year":"2023","unstructured":"Takahashi A, Namikawa K, Ogata D et al (2023) Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma. J Dermatol 50:525\u2013535. https:\/\/doi.org\/10.1111\/1346-8138.16669","journal-title":"J Dermatol"},{"key":"2755_CR20","doi-asserted-by":"publisher","first-page":"17967","DOI":"10.1002\/cam4.6438","volume":"12","author":"K Namikawa","year":"2023","unstructured":"Namikawa K, Ito T, Yoshikawa S et al (2023) Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: a multi-center retrospective study in Japan (b-check-RWD study). Cancer Med 12:17967\u201317980. https:\/\/doi.org\/10.1002\/cam4.6438","journal-title":"Cancer Med"},{"key":"2755_CR21","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s11864-022-00946-4","volume":"23","author":"C Menzer","year":"2022","unstructured":"Menzer C, Hassel JC (2022) Targeted therapy for melanomas without BRAF V600 mutations. Curr Treat Options Oncol 23:831\u2013842. https:\/\/doi.org\/10.1007\/s11864-022-00946-4","journal-title":"Curr Treat Options Oncol"},{"key":"2755_CR22","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.ejca.2021.08.015","volume":"157","author":"T Steeb","year":"2021","unstructured":"Steeb T, Wessely A, Petzold A et al (2021) c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis. Eur J Cancer 157:348\u2013357. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.015","journal-title":"Eur J Cancer"},{"key":"2755_CR23","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1158\/1078-0432.CCR-21-3872","volume":"28","author":"M Schuler","year":"2022","unstructured":"Schuler M, Zimmer L, Kim KB et al (2022) Phase Ib\/II trial of ribociclib in combination with binimetinib in patients with NRAS-mutant melanoma. Clin Cancer Res 28:3002\u20133010. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3872","journal-title":"Clin Cancer Res"},{"key":"2755_CR24","unstructured":"National Comprehensive Cancer Network (2025) Melanoma; Cutaneous, Version: 1.2025, NCCN clinical practice guidelines in oncology. Available from: https:\/\/www.nccn.org\/home Accessed January 17, 2025"},{"key":"2755_CR25","doi-asserted-by":"publisher","first-page":"5815","DOI":"10.1158\/1078-0432.CCR-18-1397","volume":"24","author":"LS Gottesdiener","year":"2018","unstructured":"Gottesdiener LS, O\u2019Connor S, Busam KJ et al (2018) Rates of ERBB2 alterations across melanoma subtypes and a complete response to trastuzumab extensive in an ERBB2-amplified acral melanoma. Clin Cancer Res 24:5815\u20135819. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1397","journal-title":"Clin Cancer Res"},{"key":"2755_CR26","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.gendis.2022.11.014","volume":"10","author":"R Jiang","year":"2023","unstructured":"Jiang R, Liang X, Tao Y et al (2023) Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma. Genes Dis 10:1755\u20131758. https:\/\/doi.org\/10.1016\/j.gendis.2022.11.014","journal-title":"Genes Dis"},{"key":"2755_CR27","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1111\/pcmr.12388","volume":"28","author":"AM Menzies","year":"2015","unstructured":"Menzies AM, Yeh I, Botton T et al (2015) Clinical activity of the MEK inhibitor trametinib in metastatic melanoma containing BRAF kinase fusion. Pigment Cell Melanoma Res 28:607\u2013610. https:\/\/doi.org\/10.1111\/pcmr.12388","journal-title":"Pigment Cell Melanoma Res"},{"key":"2755_CR28","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1172\/JCI123089","volume":"129","author":"CR McEvoy","year":"2019","unstructured":"McEvoy CR, Xu H, Smith K et al (2019) Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. J Clin Invest 129:1940\u20131945. https:\/\/doi.org\/10.1172\/JCI123089","journal-title":"J Clin Invest"},{"key":"2755_CR29","first-page":"39","volume":"2","author":"GK Kim","year":"2009","unstructured":"Kim GK, Del Rosso JQ, Bellew S (2009) Skin cancer in Asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol 2:39\u201342","journal-title":"J Clin Aesthet Dermatol"},{"key":"2755_CR30","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3390\/cancers16101800","volume":"16","author":"R Jiang","year":"2024","unstructured":"Jiang R, Fritz M, Que SKT (2024) Cutaneous squamous cell carcinoma: an updated review. Cancers (Basel) 16:1800. https:\/\/doi.org\/10.3390\/cancers16101800","journal-title":"Cancers (Basel)"},{"key":"2755_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.jaad.2010.02.057","volume":"64","author":"C Riddel","year":"2011","unstructured":"Riddel C, Rashid R, Thomas V (2011) Ungual and periungual human papillomavirus-associated squamous cell carcinoma: a review. J Am Acad Dermatol 64:1147\u20131153. https:\/\/doi.org\/10.1016\/j.jaad.2010.02.057","journal-title":"J Am Acad Dermatol"},{"key":"2755_CR32","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17592","author":"J Kato","year":"2024","unstructured":"Kato J, Hida T, Idogawa M et al (2024) The genomic landscape of cutaneous squamous cell carcinoma in Japan. J Dermatol. https:\/\/doi.org\/10.1111\/1346-8138.17592","journal-title":"J Dermatol"},{"key":"2755_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D et al (2017) Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9:34. https:\/\/doi.org\/10.1186\/s13073-017-0424-2","journal-title":"Genome Med"},{"key":"2755_CR34","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM (2017) Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med 377:2500\u20132501. https:\/\/doi.org\/10.1056\/NEJMc1713444","journal-title":"N Engl J Med"},{"key":"2755_CR35","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","volume":"20","author":"CR Pickering","year":"2014","unstructured":"Pickering CR, Zhou JH, Lee JJ et al (2014) Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res 20:6582\u20136592. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1768","journal-title":"Clin Cancer Res"},{"key":"2755_CR36","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41525-021-00226-4","volume":"6","author":"D Chang","year":"2021","unstructured":"Chang D, Shain AH (2021) The landscape of driver mutations in cutaneous squamous cell carcinoma. NPJ Genom Med 6:61. https:\/\/doi.org\/10.1038\/s41525-021-00226-4","journal-title":"NPJ Genom Med"},{"key":"2755_CR37","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","volume":"32","author":"BGM Hughes","year":"2021","unstructured":"Hughes BGM, Munoz-Couselo E, Mortier L et al (2021) Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Ann Oncol 32:1276\u20131285. https:\/\/doi.org\/10.1016\/j.annonc.2021.07.008","journal-title":"Ann Oncol"},{"key":"2755_CR38","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","volume":"92","author":"BGM Hughes","year":"2025","unstructured":"Hughes BGM, Guminski A, Bowyer S et al (2025) A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6. J Am Acad Dermatol 92:68\u201377. https:\/\/doi.org\/10.1016\/j.jaad.2024.06.108","journal-title":"J Am Acad Dermatol"},{"key":"2755_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002757","volume":"9","author":"D Rischin","year":"2021","unstructured":"Rischin D, Khushalani NI, Schmults CD et al (2021) Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer 9:e002757. https:\/\/doi.org\/10.1136\/jitc-2021-002757","journal-title":"J Immunother Cancer"},{"key":"2755_CR40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000022913","volume":"99","author":"M Ishii","year":"2020","unstructured":"Ishii M, Hirai I, Tanese K et al (2020) Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study). Medicine (Baltimore) 99:e22913. https:\/\/doi.org\/10.1097\/MD.0000000000022913","journal-title":"Medicine (Baltimore)"},{"key":"2755_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","volume":"14","author":"SP Suehnholz","year":"2024","unstructured":"Suehnholz SP, Nissan MH, Zhang H et al (2024) Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov 14:49\u201365. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0467","journal-title":"Cancer Discov"},{"key":"2755_CR42","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.3390\/cancers16162904","volume":"16","author":"TM Hosseini","year":"2024","unstructured":"Hosseini TM, Park SJ, Guo T (2024) The mutational and microenvironmental landscape of cutaneous squamous cell carcinoma: a review. Cancers (Basel) 16:2904. https:\/\/doi.org\/10.3390\/cancers16162904","journal-title":"Cancers (Basel)"},{"key":"2755_CR43","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jaad.2023.07.1051","volume":"91","author":"RR Shah","year":"2024","unstructured":"Shah RR, Shah K, Wilson BN et al (2024) Extramammary Paget\u2019s disease. Part I. epidemiology, pathogenesis, clinical features, and diagnosis. J Am Acad Dermatol 91:409\u2013418. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1051","journal-title":"J Am Acad Dermatol"},{"key":"2755_CR44","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jaad.2023.11.057","volume":"90","author":"O Iwasawa","year":"2024","unstructured":"Iwasawa O, Miyagawa T, Omatsu J et al (2024) Mutational landscape of advanced extramammary Paget\u2019s disease with comprehensive genomic profiling tests: a cohort study in a Japanese real-world setting. J Am Acad Dermatol 90:842\u2013845. https:\/\/doi.org\/10.1016\/j.jaad.2023.11.057","journal-title":"J Am Acad Dermatol"},{"key":"2755_CR45","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1093\/bjd\/ljae337","volume":"192","author":"O Iwasawa","year":"2024","unstructured":"Iwasawa O, Ikegami M, Miyagawa T et al (2024) Association of genetic alterations with prognosis in extramammary Paget disease: Insights into the involvement of somatic CDKN2A variants in patients with a poor prognosis. Br J Dermatol 192:46\u201354. https:\/\/doi.org\/10.1093\/bjd\/ljae337","journal-title":"Br J Dermatol"},{"key":"2755_CR46","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1158\/1078-0432.CCR-20-3205","volume":"27","author":"Y Ishida","year":"2021","unstructured":"Ishida Y, Kakiuchi N, Yoshida K et al (2021) Unbiased detection of driver mutations in extramammary Paget\u2019s disease. Clin Cancer Res 27:1756\u20131765. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3205","journal-title":"Clin Cancer Res"},{"key":"2755_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17500","author":"M Narasaki","year":"2024","unstructured":"Narasaki M, Kato J, Sato S et al (2024) Extramammary Paget\u2019s disease treated with of antiprogrammed cell death protein 1 therapy after docetaxel therapy failure. J Dermatol. https:\/\/doi.org\/10.1111\/1346-8138.17500","journal-title":"J Dermatol"},{"key":"2755_CR48","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jid.2018.08.030","volume":"139","author":"G Zhang","year":"2019","unstructured":"Zhang G, Zhou S, Zhong W et al (2019) Whole-exome sequencing reveals frequent mutations in chromatin remodeling genes in mammary and extramammary Paget\u2019s diseases. J Invest Dermatol 139:789\u2013795. https:\/\/doi.org\/10.1016\/j.jid.2018.08.030","journal-title":"J Invest Dermatol"},{"key":"2755_CR49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s10147-014-0686-2","volume":"20","author":"Y Tokuda","year":"2015","unstructured":"Tokuda Y, Arakura F, Uhara H (2015) Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget\u2019s disease. Int J Clin Oncol 20:194\u2013197. https:\/\/doi.org\/10.1007\/s10147-014-0686-2","journal-title":"Int J Clin Oncol"},{"key":"2755_CR50","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/1346-8138.13200","volume":"43","author":"K Yoshino","year":"2016","unstructured":"Yoshino K, Fujisawa Y, Kiyohara Y et al (2016) Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget\u2019s disease. J Dermatol 43:633\u2013637. https:\/\/doi.org\/10.1111\/1346-8138.13200","journal-title":"J Dermatol"},{"key":"2755_CR51","doi-asserted-by":"publisher","first-page":"e1201","DOI":"10.1093\/oncolo\/oyae097","volume":"29","author":"I Hirai","year":"2024","unstructured":"Hirai I, Tanese K, Nakamura Y et al (2024) Phase II clinical trial of docetaxel and trastuzumab for HER2-positive advanced extramammary Paget\u2019s disease (EMPD-HER2DOC). Oncologist 29:e1201\u2013e1208. https:\/\/doi.org\/10.1093\/oncolo\/oyae097","journal-title":"Oncologist"},{"key":"2755_CR52","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1346-8138.2009.00676.x","volume":"36","author":"S Takahagi","year":"2009","unstructured":"Takahagi S, Noda H, Kamegashira A et al (2009) Metastatic extramammary Paget\u2019s disease treated with paclitaxel and trastuzumab combination chemotherapy. J Dermatol 36:457\u2013461. https:\/\/doi.org\/10.1111\/j.1346-8138.2009.00676.x","journal-title":"J Dermatol"},{"key":"2755_CR53","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/895151","volume":"2015","author":"P Barth","year":"2015","unstructured":"Barth P, Dulaimi Al-Saleem E, Edwards KW et al (2015) Metastatic extramammary Paget\u2019s disease of scrotum responds completely to single agent trastuzumab in a hemodialysis patient: case report, molecular profiling and brief review of the literature. Case Rep Oncol Med 2015:895151. https:\/\/doi.org\/10.1155\/2015\/895151","journal-title":"Case Rep Oncol Med"},{"key":"2755_CR54","doi-asserted-by":"publisher","DOI":"10.1200\/PO.20.00073","author":"M Stasenko","year":"2020","unstructured":"Stasenko M, Jayakumaran G, Cowan R et al (2020) Genomic alterations as potential therapeutic targets in extramammary Paget\u2019s disease of the vulva. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.20.00073","journal-title":"JCO Precis Oncol"},{"key":"2755_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adk8832","author":"T Minowa","year":"2024","unstructured":"Minowa T, Murata K, Mizue Y et al (2024) Single-cell profiling of acral melanoma infiltrating lymphocytes reveals a suppressive tumor microenvironment. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.adk8832","journal-title":"Sci Transl Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02755-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02755-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T06:04:18Z","timestamp":1745301858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02755-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2755"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02755-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author (T.H.) received research grants from the Maruho Takagi Dermatology Foundation and the Suhara Memorial Foundation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}